Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 J&J To Acquire Aragon | Contract Pharma

What are you searching for?

Sign in
Breaking News

J&J To Acquire Aragon

Gains androgen receptor antagonist program

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson has entered a definitive agreement to acquire Aragon Pharmaceuticals, a privately-held company focused on developing drugs to treat hormonally-driven cancers, for $650 million upfront and as much as $350 million based on reaching predetermined milestones. The transaction is expected to close in the third quarter of 2013.

The acquisition includes Aragon’s androgen receptor antagonist program. Its lead product candidate is a second-generation androgen receptor signaling inhibitor, ARN-509, in Phase II development for castration resistant prostate cancer (CRPC). Aragon will transfer its other assets to a newly formed company. J&J will not have an ownership stake in the new company or have rights to these products or programs.

“The acquisition of Aragon further enhances our leadership in prostate cancer drug development. ARN-509 complements Zytiga and provides the potential for exciting, novel approaches to treat prostate cancer patients,” said Peter F. Lebowitz, M.D., Ph.D., global therapeutic area head, Oncology for Janssen R&D. “Prostate cancer is one of our main areas of focus, and we are pleased to be adding ARN-509 to our portfolio.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics